ICVX RSI Chart
Last 30 days
0.1%
Last 90 days
45.8%
Trailing 12 Months
87.2%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2022 | 6.4M | 4.5M | 2.7M | 582.0K |
2021 | 3.2M | 4.7M | 6.3M | 7.8M |
2020 | 0 | 0 | 0 | 1.6M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Feb 19, 2024 | shiver john w. | sold | - | - | -8,066 | - |
Feb 19, 2024 | simpson adam k. | sold | - | - | -654,076 | - |
Feb 19, 2024 | mcdade mark | sold | - | - | -55,786 | - |
Feb 19, 2024 | fields heidi | sold | - | - | -11,376 | - |
Feb 19, 2024 | shiver john w. | back to issuer | - | - | -2,833 | - |
Feb 19, 2024 | mcdade mark | sold | - | - | -3,510,230 | - |
Feb 19, 2024 | veneman ann m | sold | - | - | -11,209 | - |
Feb 19, 2024 | veneman ann m | back to issuer | - | - | -2,834 | - |
Feb 19, 2024 | russo thomas joseph | sold | - | - | -39,367 | - |
Feb 19, 2024 | fields heidi | back to issuer | - | - | -2,917 | - |
Which funds bought or sold ICVX recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Apr 25, 2024 | SIMPLEX TRADING, LLC | sold off | -100 | -10,000 | - | -% |
Apr 25, 2024 | Bank of New York Mellon Corp | sold off | -100 | -1,463,080 | - | -% |
Apr 23, 2024 | AMALGAMATED BANK | sold off | -100 | -33,000 | - | -% |
Apr 22, 2024 | Vivo Capital, LLC | sold off | -100 | -26,864,000 | - | -% |
Apr 22, 2024 | MetLife Investment Management, LLC | added | 18.59 | 138,920 | 237,330 | -% |
Apr 19, 2024 | Cutler Group LLC / CA | sold off | -100 | -7,000 | - | -% |
Apr 18, 2024 | Allspring Global Investments Holdings, LLC | sold off | -100 | -294,838 | - | -% |
Apr 11, 2024 | Fortitude Family Office, LLC | sold off | -100 | -8,810 | - | -% |
Apr 09, 2024 | SYQUANT CAPITAL SAS | sold off | -100 | -3,005,000 | - | -% |
Mar 11, 2024 | VANGUARD GROUP INC | reduced | -3.59 | 14,130,000 | 28,841,700 | -% |
Unveiling Icosavax, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Icosavax, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 41.2B | 6.8B | -8.75 | 6.02 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 18.0B | 1.8B | -41 | 9.87 | ||||
BMRN | 15.4B | 2.5B | 74.73 | 6.21 | ||||
INCY | 11.6B | 3.7B | 19.41 | 3.14 | ||||
MID-CAP | ||||||||
APLS | 6.0B | 396.6M | -11.37 | 15.16 | ||||
BBIO | 4.4B | - | -6.7 | 60.35 | ||||
AXSM | 3.4B | 270.6M | -14.22 | 12.57 | ||||
ACAD | 2.8B | 726.4M | -44.9 | 3.79 | ||||
ARWR | 2.7B | 240.7M | -9.23 | 12.18 | ||||
SMALL-CAP | ||||||||
CPRX | 1.8B | 398.2M | 24.58 | 4.41 | ||||
NVAX | 569.6M | 983.7M | -1.05 | 0.58 | ||||
CRBP | 361.2M | 881.7K | -8.1 | 466.16 | ||||
INO | 247.0M | 4.9M | -1.83 | 50.76 | ||||
IBIO | 6.1M | 2.1M | -0.22 | 2.14 |
Icosavax, Inc. News
Income Statement (Quarterly) | ||||||||||
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 |
Revenue | - | - | - | - | 582,000 | 2,070,000 | 1,827,000 | 1,904,000 | 2,001,000 | - |
Operating Expenses | 8.6% | 25,131,000 | 23,143,000 | 23,131,000 | 24,235,000 | 20,281,000 | 36,240,000 | 10,498,000 | 6,644,000 | - |
S&GA Expenses | 16.7% | 8,938,000 | 7,659,000 | 7,311,000 | 6,322,000 | 6,218,000 | 25,357,000 | 2,221,000 | 1,091,000 | - |
R&D Expenses | 4.6% | 16,193,000 | 15,484,000 | 15,820,000 | 17,913,000 | 14,063,000 | 10,883,000 | 8,277,000 | 5,553,000 | - |
Interest Expenses | - | - | - | - | 120,000 | - | - | - | - | - |
Net Income | -7.4% | -23,613,000 | -21,976,000 | -22,636,000 | -23,533,000 | -18,182,000 | -34,386,000 | -8,552,000 | -5,851,000 | -4,608,000 |
Net Income Margin | -384.3% | -157 | -32.55 | -22.04 | -13.26 | -8.58 | -8.54 | -5.22 | -6.71 | -11.67 |
Free Cashflow | 33.5% | -14,183,000 | -21,333,000 | -18,690,000 | -18,582,000 | -13,459,000 | -9,341,000 | -12,430,000 | -4,316,000 | - |
Balance Sheet | ||||||||||||
Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2020Q4 |
Assets | -6.6% | 251 | 269 | 220 | 239 | 244 | 260 | 277 | 288 | 301 | 119 | 16.00 |
Current Assets | -6.5% | 235 | 252 | 202 | 224 | 229 | 249 | 270 | 287 | 300 | 116 | 16.00 |
Cash Equivalents | -59.2% | 63.00 | 155 | 50.00 | 60.00 | 66.00 | 109 | 262 | 281 | 294 | 112 | 15.00 |
Net PPE | -6.0% | 11.00 | 12.00 | 12.00 | 12.00 | 12.00 | 8.00 | 3.00 | 1.00 | 1.00 | 1.00 | 0.00 |
Liabilities | -11.2% | 19.00 | 21.00 | 20.00 | 21.00 | 18.00 | 17.00 | 17.00 | 9.00 | 8.00 | 6.00 | 13.00 |
Current Liabilities | -13.2% | 13.00 | 15.00 | 13.00 | 14.00 | 13.00 | 12.00 | 14.00 | 9.00 | 8.00 | 6.00 | 6.00 |
Shareholder's Equity | -6.2% | 232 | 248 | 200 | 218 | 226 | 242 | 260 | 278 | 292 | - | - |
Retained Earnings | -9.3% | -258 | -236 | -210 | -185 | -162 | -140 | -117 | -94.07 | -75.89 | -41.50 | -27.10 |
Additional Paid-In Capital | 1.4% | 491 | 485 | 411 | 404 | 388 | 383 | 377 | 372 | 368 | 2.00 | 0.00 |
Shares Outstanding | 0.3% | 50.00 | 50.00 | 41.00 | 41.00 | 40.00 | 40.00 | 39.00 | 39.00 | 26.00 | 3.00 | 3.00 |
Cashflow (Quarterly) | |||||||||||||||
Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 |
Cashflow From Operations | 1.3% | -18,972 | -19,222 | -21,649 | -11,633 | -17,378 | -15,204 | -17,460 | -13,036 | -9,326 | -11,996 | -4,182 | - | - | - |
Share Based Compensation | 4.6% | 6,602 | 6,311 | 6,000 | 6,158 | 5,434 | 5,552 | 4,550 | 3,677 | 23,670 | 1,408 | 276 | - | - | - |
Cashflow From Investing | -230.2% | -72,654 | 55,822 | 12,027 | -4,113 | -26,183 | -138,031 | -1,122 | -423 | -15.00 | -434 | -134 | - | - | - |
Cashflow From Financing | -100.3% | -208 | 68,071 | 117 | 10,087 | -279 | 223 | 276 | 260 | 191,500 | -767 | 113,779 | - | - | - |
Condensed Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Grant revenue | $ 0 | $ 0 | $ 0 | $ 582 |
Operating expenses: | ||||
Research And Development Expenses | 16,668 | 15,484 | 53,851 | 49,217 |
General and administrative | 8,607 | 7,659 | 26,901 | 21,292 |
Total operating expenses | 25,275 | 23,143 | 80,752 | 70,509 |
Loss from operations | (25,275) | (23,143) | (80,752) | (69,927) |
Other income (expense): | ||||
Interest and other | 3,234 | 1,167 | 7,653 | 1,782 |
Total other income | 3,234 | 1,167 | 7,653 | 1,782 |
Net loss | (22,041) | (21,976) | (73,099) | (68,145) |
Comprehensive loss: | ||||
Unrealized losses on available-for-sale debt securities | 18 | (334) | 355 | (609) |
Comprehensive loss | $ (22,023) | $ (22,310) | $ (72,744) | $ (68,754) |
Net loss per share, basic | $ (0.44) | $ (0.55) | $ (1.61) | $ (1.72) |
Net loss per share, diluted | $ (0.44) | $ (0.55) | $ (1.61) | $ (1.72) |
Weighted-average common shares outstanding, basic | 50,030,759 | 39,748,984 | 45,411,654 | 39,623,357 |
Weighted-average common shares outstanding, diluted | 50,030,759 | 39,748,984 | 45,411,654 | 39,623,357 |
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Sep. 30, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 63,239 | $ 58,846 |
Restricted cash | 0 | 1,061 |
Short-term investments | 165,967 | 159,461 |
Prepaid expenses and other current assets | 6,101 | 4,545 |
Total current assets | 235,307 | 223,913 |
ROU assets - operating leases | 2,975 | 3,247 |
Property and equipment, net | 11,400 | 11,517 |
Other Assets Noncurrent | 1,614 | 0 |
Total assets | 251,296 | 238,677 |
Current liabilities: | ||
Accounts payable | 1,239 | 2,892 |
Accrued and other current liabilities | 9,606 | 8,759 |
Current portion of operating lease liabilities | 2,185 | 2,137 |
Total current liabilities | 13,030 | 13,788 |
Lease liabilities, net of current portion | 5,886 | 6,658 |
Other noncurrent liabilities | 0 | 69 |
Total liabilities | 18,916 | 20,515 |
Commitments and contingencies (Note 2) | ||
Stockholders' equity | ||
Common stock, $0.0001 par value; 500,000,000 shares authorized at September 30, 2023 and December 31, 2022; 50,088,633 and 41,177,706 shares issued as of September 30, 2023 and December 31, 2022, respectively; 50,088,633 and 41,095,564 shares outstanding as of September 30, 2023 and December 31, 2022, respectively | 7 | 6 |
Additional paid-in capital | 491,347 | 404,386 |
Accumulated other comprehensive loss | (48) | (403) |
Accumulated deficit | (258,926) | (185,827) |
Total stockholders' equity | 232,380 | 218,162 |
Total liabilities and stockholders' equity | $ 251,296 | $ 238,677 |